Incyte Highlights Results from the P-II Trial of Povorcitinib for the Treatment of Prurigo Nodularis at AAD’24
Shots:
- The P-II study investigates the safety & efficacy of povorcitinib (15mg, 45mg, 75mg) vs PBO for treating prurigo nodularis (PN) patients (n=146, ≥18yrs.) with inadequate response or intolerant to previous PN treatment, for over 16wks. followed by a 24wk. extension
- The 1EP of trial demonstrated a 36.1%, 44.4% & 54.1% of patients attained NRS4 score vs 8.1% at wk. 16 & median times to itch NRS4 of 58, 35 & 17 days for the three dosing levels, respectively
- The 2EP showed an IGA-TS score of 0 or 1 with a ≥2-grade improvement from baseline in 13.9%, 30.6% & 48.6% of patients vs 5.4% and both itch NRS4 & IGA-TS in 8.3%, 22.2% & 35.1% of patients vs 2.5% at wk. 16
Ref: Incyte | Image: Incyte
Related News:- Incyte Reports the US FDA’s Acceptance of BLA for Axatilimab with Priority Review to Treat Chronic Graft-Versus-Host Disease (GVHD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
